NO305584B1 - FremgangsmÕte for fremstilling av et farmas°ytisk preparat av et ikke-glykosylert t-PA-derivat K1K2P pro - Google Patents

FremgangsmÕte for fremstilling av et farmas°ytisk preparat av et ikke-glykosylert t-PA-derivat K1K2P pro Download PDF

Info

Publication number: NO305584B1
Authority: NO; Norway
Prior art keywords: mmol; acid; citrate; pharmaceutical preparation; preparation according
Prior art date: 1989-12-20

Application number

NO913119A

Other languages

English (en)

Norwegian (no)

Other versions

NO913119L (no

NO913119D0 (no

Inventor

Ulrich Kohnert

Rainer Rudolph

Original Assignee

Boehringer Mannheim Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-12-20

Filing date

1991-08-09

Publication date

1999-06-28

1991-08-09 Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh

1991-08-09 Publication of NO913119L publication Critical patent/NO913119L/no

1991-08-09 Publication of NO913119D0 publication Critical patent/NO913119D0/no

1999-06-28 Publication of NO305584B1 publication Critical patent/NO305584B1/no

Links

238000004519 manufacturing process Methods 0.000 title claims description 14
238000002360 preparation method Methods 0.000 title claims description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims abstract description 27
239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 19
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 12
238000000034 method Methods 0.000 claims abstract description 12
239000004475 Arginine Substances 0.000 claims abstract description 9
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 9
150000001875 compounds Chemical class 0.000 claims abstract description 8
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 7
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims abstract description 6
229930091371 Fructose Natural products 0.000 claims abstract description 6
239000005715 Fructose Substances 0.000 claims abstract description 6
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 6
229960005070 ascorbic acid Drugs 0.000 claims abstract description 6
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 6
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 6
230000002255 enzymatic effect Effects 0.000 claims abstract description 6
229960002442 glucosamine Drugs 0.000 claims abstract description 6
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims abstract description 6
235000010323 ascorbic acid Nutrition 0.000 claims abstract description 4
239000011668 ascorbic acid Substances 0.000 claims abstract description 4
239000002718 pyrimidine nucleoside Substances 0.000 claims abstract description 4
239000002719 pyrimidine nucleotide Substances 0.000 claims abstract description 4
150000003230 pyrimidines Chemical class 0.000 claims abstract description 4
125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims abstract description 3
150000001735 carboxylic acids Chemical group 0.000 claims abstract description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 3
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 10
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 10
239000000243 solution Substances 0.000 claims description 10
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 10
-1 hydroxy- Chemical class 0.000 claims description 9
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 8
VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 claims description 8
XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 claims description 8
150000001413 amino acids Chemical class 0.000 claims description 7
239000007924 injection Substances 0.000 claims description 7
238000002347 injection Methods 0.000 claims description 7
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 6
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 6
239000000872 buffer Substances 0.000 claims description 6
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 6
KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims description 6
GSPZXGHHFDORDC-UHFFFAOYSA-N 2-(diaminomethylideneamino)butanoic acid Chemical compound CCC(C(O)=O)N=C(N)N GSPZXGHHFDORDC-UHFFFAOYSA-N 0.000 claims description 5
KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical class OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims description 5
BLFRQYKZFKYQLO-UHFFFAOYSA-N 4-aminobutan-1-ol Chemical compound NCCCCO BLFRQYKZFKYQLO-UHFFFAOYSA-N 0.000 claims description 5
LQGKDMHENBFVRC-UHFFFAOYSA-N 5-aminopentan-1-ol Chemical compound NCCCCCO LQGKDMHENBFVRC-UHFFFAOYSA-N 0.000 claims description 5
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims description 5
XDOLZJYETYVRKV-UHFFFAOYSA-N 7-Aminoheptanoic acid Chemical compound NCCCCCCC(O)=O XDOLZJYETYVRKV-UHFFFAOYSA-N 0.000 claims description 5
UQXNEWQGGVUVQA-UHFFFAOYSA-N 8-aminooctanoic acid Chemical compound NCCCCCCCC(O)=O UQXNEWQGGVUVQA-UHFFFAOYSA-N 0.000 claims description 5
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 5
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 5
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
239000004472 Lysine Substances 0.000 claims description 5
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 5
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 5
QCTBMLYLENLHLA-UHFFFAOYSA-N aminomethylbenzoic acid Chemical compound NCC1=CC=C(C(O)=O)C=C1 QCTBMLYLENLHLA-UHFFFAOYSA-N 0.000 claims description 5
229960003375 aminomethylbenzoic acid Drugs 0.000 claims description 5
239000001530 fumaric acid Chemical class 0.000 claims description 5
235000011087 fumaric acid Nutrition 0.000 claims description 5
TUHVEAJXIMEOSA-UHFFFAOYSA-N gamma-guanidinobutyric acid Natural products NC(=[NH2+])NCCCC([O-])=O TUHVEAJXIMEOSA-UHFFFAOYSA-N 0.000 claims description 5
NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 claims description 5
239000004310 lactic acid Chemical class 0.000 claims description 5
235000014655 lactic acid Nutrition 0.000 claims description 5
229960003104 ornithine Drugs 0.000 claims description 5
229960003080 taurine Drugs 0.000 claims description 5
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 5
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical class OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 4
PWGJDPKCLMLPJW-UHFFFAOYSA-N 1,8-diaminooctane Chemical compound NCCCCCCCCN PWGJDPKCLMLPJW-UHFFFAOYSA-N 0.000 claims description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Chemical class OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 4
PWSKHLMYTZNYKO-UHFFFAOYSA-N heptane-1,7-diamine Chemical compound NCCCCCCCN PWSKHLMYTZNYKO-UHFFFAOYSA-N 0.000 claims description 4
239000001630 malic acid Chemical class 0.000 claims description 4
229940099690 malic acid Drugs 0.000 claims description 4
235000011090 malic acid Nutrition 0.000 claims description 4
SXJVFQLYZSNZBT-UHFFFAOYSA-N nonane-1,9-diamine Chemical compound NCCCCCCCCCN SXJVFQLYZSNZBT-UHFFFAOYSA-N 0.000 claims description 4
GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 4
229960000401 tranexamic acid Drugs 0.000 claims description 4
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 3
239000005700 Putrescine Substances 0.000 claims description 3
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 3
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims description 3
150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
229940104302 cytosine Drugs 0.000 claims description 3
229940104230 thymidine Drugs 0.000 claims description 3
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims description 3
229940045145 uridine Drugs 0.000 claims description 3
125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 2
239000002211 L-ascorbic acid Substances 0.000 claims description 2
235000000069 L-ascorbic acid Nutrition 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
239000000126 substance Substances 0.000 claims description 2
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
SUTWPJHCRAITLU-UHFFFAOYSA-N 6-aminohexan-1-ol Chemical compound NCCCCCCO SUTWPJHCRAITLU-UHFFFAOYSA-N 0.000 claims 1
229940124277 aminobutyric acid Drugs 0.000 claims 1
229940116298 l- malic acid Drugs 0.000 claims 1
229930194542 Keto Chemical group 0.000 abstract description 3
239000002253 acid Substances 0.000 abstract description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 3
125000000468 ketone group Chemical group 0.000 abstract description 3
239000003814 drug Substances 0.000 abstract description 2
239000004480 active ingredient Substances 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
125000002947 alkylene group Chemical group 0.000 abstract 1
125000002993 cycloalkylene group Chemical group 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 20
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 20
229960000187 tissue plasminogen activator Drugs 0.000 description 20
239000000203 mixture Substances 0.000 description 15
238000009472 formulation Methods 0.000 description 11
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
230000000694 effects Effects 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
239000000654 additive Substances 0.000 description 3
229940012957 plasmin Drugs 0.000 description 3
102000013566 Plasminogen Human genes 0.000 description 2
108010051456 Plasminogen Proteins 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000007979 citrate buffer Substances 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 2
230000007017 scission Effects 0.000 description 2
241000894006 Bacteria Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
229920006158 high molecular weight polymer Polymers 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000000523 sample Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
VSRBKQFNFZQRBM-UHFFFAOYSA-N tuaminoheptane Chemical compound CCCCCC(C)N VSRBKQFNFZQRBM-UHFFFAOYSA-N 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Oil, Petroleum & Natural Gas (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO913119A 1989-12-20 1991-08-09 FremgangsmÕte for fremstilling av et farmas°ytisk preparat av et ikke-glykosylert t-PA-derivat K1K2P pro NO305584B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE3942144A DE3942144A1 (de)	1989-12-20	1989-12-20	Stabilisierung von k1k2p pro
PCT/EP1990/002248 WO1991008763A1 (fr)	1989-12-20	1990-12-19	Stabilisation de k1k2p pro

Publications (3)

Publication Number	Publication Date
NO913119L NO913119L (no)	1991-08-09
NO913119D0 NO913119D0 (no)	1991-08-09
NO305584B1 true NO305584B1 (no)	1999-06-28

Family

ID=6395927

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO913119A NO305584B1 (no)	1989-12-20	1991-08-09	FremgangsmÕte for fremstilling av et farmas°ytisk preparat av et ikke-glykosylert t-PA-derivat K1K2P pro

Country Status (13)

Country	Link
EP (1)	EP0458949B1 (fr)
JP (1)	JPH0657662B2 (fr)
KR (1)	KR920700685A (fr)
AT (1)	ATE121948T1 (fr)
AU (1)	AU624761B2 (fr)
CA (1)	CA2046930C (fr)
DE (2)	DE3942144A1 (fr)
DK (1)	DK0458949T3 (fr)
ES (1)	ES2071978T3 (fr)
FI (1)	FI98601C (fr)
HU (2)	HU208638B (fr)
NO (1)	NO305584B1 (fr)
WO (1)	WO1991008763A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3942141A1 (de) *	1989-12-20	1991-06-27	Boehringer Mannheim Gmbh	K2p pro-stabilisierung
EP0639202B1 (fr) *	1992-04-30	1998-11-25	Cor Therapeutics, Inc.	Compositions stables a base de polypeptides
DE4405426A1 (de) *	1994-02-21	1995-08-24	Boehringer Mannheim Gmbh	Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZW14486A1 (en) *	1985-07-29	1986-10-22	Smithkline Beckman Corp	Pharmaceutical dosage unit
US4777043A (en) *	1985-12-17	1988-10-11	Genentech, Inc.	Stabilized human tissue plasminogen activator compositions
DE3718889A1 (de) *	1987-06-05	1988-12-22	Behringwerke Ag	Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin
DE3923339A1 (de) *	1989-05-31	1990-12-06	Boehringer Mannheim Gmbh	Gewebs-plasminogen-aktivator-derivat

1989
- 1989-12-20 DE DE3942144A patent/DE3942144A1/de not_active Withdrawn
1990
- 1990-12-19 WO PCT/EP1990/002248 patent/WO1991008763A1/fr not_active Ceased
- 1990-12-19 HU HU912741A patent/HU208638B/hu not_active IP Right Cessation
- 1990-12-19 AT AT91901723T patent/ATE121948T1/de not_active IP Right Cessation
- 1990-12-19 DE DE59009025T patent/DE59009025D1/de not_active Expired - Fee Related
- 1990-12-19 KR KR1019910700936A patent/KR920700685A/ko not_active Ceased
- 1990-12-19 ES ES91901723T patent/ES2071978T3/es not_active Expired - Lifetime
- 1990-12-19 HU HU912741A patent/HUT59611A/hu unknown
- 1990-12-19 EP EP91901723A patent/EP0458949B1/fr not_active Expired - Lifetime
- 1990-12-19 JP JP3502061A patent/JPH0657662B2/ja not_active Expired - Lifetime
- 1990-12-19 DK DK91901723.6T patent/DK0458949T3/da active
- 1990-12-19 AU AU70461/91A patent/AU624761B2/en not_active Ceased
- 1990-12-19 CA CA002046930A patent/CA2046930C/fr not_active Expired - Fee Related
1991
- 1991-08-09 NO NO913119A patent/NO305584B1/no not_active IP Right Cessation
- 1991-08-19 FI FI913906A patent/FI98601C/fi active

Also Published As

Publication number	Publication date
WO1991008763A1 (fr)	1991-06-27
JPH0657662B2 (ja)	1994-08-03
NO913119L (no)	1991-08-09
ES2071978T3 (es)	1995-07-01
AU624761B2 (en)	1992-06-18
CA2046930A1 (fr)	1991-06-21
DE59009025D1 (de)	1995-06-08
ATE121948T1 (de)	1995-05-15
FI98601C (fi)	1997-07-25
AU7046191A (en)	1991-07-18
HU912741D0 (en)	1992-01-28
DK0458949T3 (da)	1995-10-02
HU208638B (en)	1993-12-28
FI98601B (fi)	1997-04-15
FI913906A0 (fi)	1991-08-19
HUT59611A (en)	1992-06-29
JPH04502606A (ja)	1992-05-14
CA2046930C (fr)	1997-01-14
KR920700685A (ko)	1992-08-10
EP0458949B1 (fr)	1995-05-03
EP0458949A1 (fr)	1991-12-04
NO913119D0 (no)	1991-08-09
DE3942144A1 (de)	1991-06-27

Legal Events

Date	Code	Title	Description
2003-07-28	MM1K	Lapsed by not paying the annual fees	Free format text: LAPSED IN JUNE 2003

Publication	Publication Date	Title
JP3868997B2 (ja)	2007-01-17	プラスミノーゲン活性化因子を含有する医薬製剤
KR890000103A (ko)	1989-03-11	조직 플라스미노겐 활성화제(t-PA) 활성을 갖는 단백질의 고농도 용액의 제조방법, t-PA 활성을 갖는 단백질을 함유하는 용액, 및 인체 및 수의약제에 있어서 용액의 용도
NO305585B1 (no)	1999-06-28	FremgangsmÕte for fremstillig av et farmas°ytisk preparat av et ikke-glykosylert t-PA-derivat
US5409699A (en)	1995-04-25	Compositions containing glycosylated molecules having human tissue type plasminogen activator enzymatic activity
JPS638339A (ja)	1988-01-14	非経口投与用医薬組成物
NO305583B1 (no)	1999-06-28	FremgangsmÕte for fremstilling av et farmas°ytisk preparat av et ikke-glykosylert t-PA
NO305584B1 (no)	1999-06-28	FremgangsmÕte for fremstilling av et farmas°ytisk preparat av et ikke-glykosylert t-PA-derivat K1K2P pro
US5366730A (en)	1994-11-22	Stabilized compositions having human tissue type plasminogen activator enzymatic activity
JPH0273022A (ja)	1990-03-13	組織プラスミノーゲン活性化因子を用いた薬学的製剤
CA2046598C (fr)	1997-01-14	Solubilisation de l'activateur plasminogene tissulaire
EP0419252A1 (fr)	1991-03-27	Composition thrombolytique contenant activateur plasminogène de type tissulaire ou un de ses dérivés
JPH04503525A (ja)	1992-06-25	グリコシル化されていないｔ―ＰＡ誘導体Ｋ１Ｋ２Ｐｐｒｏの製薬学的製剤および医薬品ならびに該製剤の製造方法
JP4025394B2 (ja)	2007-12-19	組織プラスミノーゲン活性化因子医薬組成物